This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alexander, K. P. Articles by Fuster, V. Search for Related Content PubMed PubMed Citation Articles by Alexander, K. P. Articles by Fuster, V.

Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up

Karen P. Alexander, MD, FACC^a, L. Kristin Newby, MD, FACC, Anne S. Hellkamp, MS, Robert A. Harrington, MD, FACC, Eric D. Peterson, MD, MPH, FACC^a, Steve Kopecky, MD, FACC, Antoly Langer, MD, FACC, Patrick O’Gara, MD, FACC^||, Christopher M. O’Connor, MD, FACC, Robert N. Daly, MS, PhD^¶, Robert M. Califf, MD, FACC, Steven Khan, MD, FACC^# and Valentin Fuster, MD, FACC^**

^a Outcomes Research and Assessment Group, The Duke Clinical Research Institute, Durham, North Carolina, USA
The Duke Clinical Research Institute, Durham, North Carolina, USA
Mayo Clinic, Rochester, Minnesota, USA
St. Michael’s Hospital, Toronto, Canada
^|| Brigham and Women’s Hospital, Boston, Massachusetts, USA
^¶ Dupont Pharmaceuticals, Wilmington, Delaware, USA
^# Cedars-Sinai Medical Center, Los Angeles, California, USA
^** Mount Sinai Medical Center, New York, New York, USA

View larger version (8K): [in a new window]   Figure 1 Cumulative incidence of death/recurrent myocardial infarction/unstable angina requiring hospitalization during follow-up period by hormone replacement therapy use category.